Nicholas A. Saccomano is CSO at ARRAY BIOPHARMA INC (ARRY). They have made 8 open-market trades across 2 companies since 2019, most recently 2026-09-21.
CIK 0001609284
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARRY | 61,813 | $211K |
| OKUR | 11,160 | $23K |
| Total | $234K |
Shares reported on the most recent Form 4, priced at the 2026-09-23 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OKUR | SELL | 2026-09-21 | 2026-09-23 | $2.97 | $259 | -11.9% | — | — |
| OKUR | SELL | 2026-06-22 | 2026-06-24 | $4.40 | $378 | +0.1% | -5.3% | -29.3% |
| OKUR | SELL | 2026-03-23 | 2026-03-24 | $4.16 | $715 | +8.8% | +22.5% | +10.8% |
| OKUR | SELL | 2025-12-22 | 2025-12-23 | $2.97 | $258 | -3.1% | +6.3% | +38.7% |
| OKUR | SELL | 2025-09-22 | 2025-09-24 | $2.62 | $231 | +8.9% | +28.2% | +9.3% |
| OKUR | SELL | 2025-06-23 | 2025-06-25 | $2.38 | $209 | -3.5% | -9.4% | -0.8% |
| OKUR | SELL | 2025-04-04 | 2025-04-08 | $2.94 | $3K | -13.6% | -36.7% | -24.4% |
| ARRY | SELL | 2019-02-07 | 2019-02-08 | $21.58 | $8.1M | +33.9% | +23.6% | +23.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.